ArticleInternational journal of preventive medicine2014
Reducing the incidence of chronic lung disease in very premature infants with aminophylline.
Article in International journal of preventive medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Care of Preterm and Term Newborns with Respiratory Conditions: A Systematic Synthesis of Evidence from Low- and Middle-Income Countries.Neonatology · 2025Pooled it
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.The Cochrane database of systematic reviews · 2024Pooled it
- Methylxanthine for the prevention and treatment of apnea in preterm infants.The Cochrane database of systematic reviews · 2023Pooled it
- Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.The Cochrane database of systematic reviews · 2016Pooled it
- Early aminophylline is a potential therapy for preventing bronchopulmonary dysplasia in premature infants: a retrospective study.BMC pediatrics · 2025Article
- Theophylline impact on weaning in oxygen-dependent infants followed in an outpatient Kangaroo Program.Frontiers in pediatrics · 2024Article
- Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants.Children (Basel, Switzerland) · 2021Review
- Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches.Clinical medicine insights. Pediatrics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study is to assess the safety and preventative effects of aminophylline on the incidence of chronic lung disease (CLD) in very premature infants.
methodsThis was a long follow-up randomized clinical trial. The prophylactic effect of aminophylline on the incidence of CLD was investigated in very premature infants. The study group received aminophylline for the 1(st) 10 days of life and control infants received no aminophylline during the 1(st) 10 days of life.
resultsFifty-two infants participated (26 aminophylline, 26 controls). Premature infants on aminophylline had clearly shorter oxygen dependency time than those in the control group. Median time of oxygen dependency was 3 (0-9.5) days and 14 (3-40.5) days in group A and C, respectively (P: 0.001). Incidence of CLD was significantly different between the two groups. Only two infants (8.7%) on aminophylline developed CLD, when compared to 11 infants (44.0%), who did not receive aminophylline (P: 0.006). No side-effects were reported in the neonates (P: 1).
conclusionsThis study supports the preventative effects of aminophylline on the incidence of CLD in very premature infants. In other words, the more premature the infants, the greater will be the preventative effect of aminophylline on the incidence of CLD.
Indexed as
Identifiers
24932388PMC4050677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.